Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
Lucid Diagnostics (Nasdaq: LUCD) will host a business update conference call and webcast on November 12, 2026, at 8:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucid Diagnostics (Nasdaq: LUCD) will host a business update conference call and webcast on November 12, 2026, at 8:30 AM ET. Chairman and CEO Lishan Aklog will discuss operations and growth strategy, while CFO Dennis McGrath will discuss third-quarter 2026 financial results. The webcast will be available through the investor relations section at luciddx.com, with a replay available for 30 days after the call.
Details
Market Reaction – LUCD
On Oct 29, the day this news came out, the latest delayed price for LUCD is 2.29% below the previous close. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $0.42. Relative volume is above average at 1.8x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast at 8:30 AM ET
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone,
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-third-quarter-2026-business-update-conference-call-and-webcast-on-november-12-2026-302923219.html
SOURCE Lucid Diagnostics